An investigation, whether switching patients with low platelet reactivity on potent ADP-receptor antagonist to the weaker clopidogrel leads to fewer bleeding events in cardiogenic shock patients, appears to be very interesting—a strategy which was already shown to be safe in AMI patients without cardiogenic shock in the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes (TROPICAL-ACS) trial [19]. The gene discussed is P2RY1; the disease is acute coronary syndrome.